Clinical trials: GLP - 1
Diabetes Mellitus, Obesity
Study of the Gut Hormone Analogue G3215 in Adult Subjects
A randomised, placebo controlled Phase I study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of G3215 in adult subjects.
- Trial name
- NCT02692040
- Testing
- G3215
- Where
- United Kingdom
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Postprandial Hypoglycemia
Role of Glucagon-Like Peptide-1 in Postprandial Hypoglycemia
It has been proposed that the rapid gastric emptying of carbohydrate containing fluids into the intestine causes hyperglycemia followed by reactive hypoglycemia.
- Trial name
- NCT01162499
- Testing
- Exendin-(9-39), Vehicle
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Diva De Leon
CABG
Effect of GLP - 1 (7-36 Amide) on Myocardial Function Following Coronary Artery Bypass (CABG) Surgery
This research is being done to see if giving a hormone called GLP-1 can improve heart function and reduce length of stay in the Cardiac Surgical Intensive Care Unit (CSICU) in people who have non-emergent coronary artery bypass…
- Trial name
- GLP-1 CABG (NCT00966654)
- Testing
- GLP-1 (7-36) amide
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Johns Hopkins University
Chronic Kidney Diseases
Effects of GLP1-RA on Ectopic Fat Deposition in Chronic Kidney Disease
Chronic kidney disease (CKD) is a burden of morbidity and mortality. Increased protein breakdown in skeletal muscle (wasting) and ectopic fat deposition are important determinants of poor clinical outcome in patient with CKD.
- Trial name
- GLIMP (NCT05254418)
- Testing
- dulaglutide injection
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Vanderbilt University Medical Center
Hypothalamic Obesity
Energy Balance & Weight Loss in Craniopharyngioma-related or Other Hypothalamic Tumors in Hypothalamic Obesity
The proposed multicenter study will test the effect of glucagon-like peptide (GLP)-1 agonist exenatide once weekly extended-release (ExQW, Bydureon®) on clinical outcomes and metabolic parameters in a double-blind…
- Trial name
- ECHO (NCT02664441)
- Testing
- Exenatide
- Where
- 3 sites in United States
- Volunteers
- 42 people
- Sponsor
- Seattle Children's Hospital
Type 2 Diabetes Mellitus
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardiovascular risk.
- Trial name
- SURPASS-CVOT (NCT04255433)
- Testing
- Tirzepatide, Dulaglutide
- Where
- 635 sites in United States, Argentina and 29 more
- Volunteers
- 13,299 people
- Sponsor
- Eli Lilly and Company
Opiate Substitution Treatment, Opioid-Related Disorders
Use of a GLP-1R Agonist to Treat Opioid Use Disorder
This research is being done to find out if liraglutide (brand name is Saxenda®) can safely and effectively reduce craving for opioids in patients with opioid use disorder, a primary factor contributing to early relapse.
- Trial name
- NCT04199728
- Testing
- Liraglutide Pen Injector
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Milton S. Hershey Medical Center
Pre-diabetes, Older Adults
Liraglutide and a Calorie Restricted Diet Augments Weight Loss and Decreases Risk of Type 2 Diabetes and CVD.
The goal of this study is to evaluate the hypothesis that the addition of liraglutide, a long-acting glucagon-like peptide 1 (GLP-1) analogue, to a calorie-restricted diet will lead to greater weight loss than will a…
- Trial name
- NCT01784965
- Testing
- liraglutide
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Stanford University
Type 2 Diabetes
A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin
The purpose of this study is to compare the safety and efficacy of the study drug tirzepatide to insulin lispro (U100) three times a day in participants with type 2 diabetes that are already on insulin glargine (U100), with or…
- Trial name
- SURPASS-6 (NCT04537923)
- Testing
- Tirzepatide, Insulin Lispro (U100)
- Where
- 135 sites in United States, Argentina and 14 more
- Volunteers
- 1,428 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
Pharmacokinetics Study of Dipeptidyl Peptidase 4 Inhibitor to Control Type 2 Diabetes Mellitus
The purpose of this study is to confirm the mechanism of reduced response to DPP-4 inhibitor in some patients with type 2 diabetes and evaluate appropriate patients to treat with DPP-4 inhibitor
- Trial name
- NCT01449747
- Testing
- Sitagliptin
- Where
- 2 sites in South Korea
- Volunteers
- 24 people
- Sponsor
- The Catholic University of Korea